Article Figures & Data
Tables
High-Risk HPV Any HPV Variable No. Reference Levels OR (95% CI) P Value OR (95% CI) P Value OR = odds ratio; CI = confidence interval; ASCUS = abnormal squamous cells of undetermined significance; NS = not significant; LSIL = low-grade squamous intraepithelial lesion; HSIL = high-grade squamous intraepithelial lesion, CIN = cervical intraepithelial neoplasia. * There are insufficient numbers of samples associated with women using an intrauterine device who also had high-risk types of HPV to include the IUD in the logistic regression. † Tobacco use is current or ever vs never. ‡ Weeks are defined as 0–7, 8–14, 15–21, 22–35, and 36+ days. Week 5 encompasses women with long menstrual cycles, using progesterone only contraceptives, or who are postmenopausal. Age 1,186 Young age Older age 0.96 (0.93–0.99) .014 0.94 (0.91–0.98) .001 Gravidity 1,177 No pregnancies One or more pregnancies 0.81 (0.65–1.00) .05 0.80 (0.64–0.99) .039 Parity 1,171 No births One or more births 0.66 (0.48–0.92) .013 0.58 (0.42–0.81) .002 Oral contraceptive use 1,177 No Yes 2.55 (1.10–5.86) .028 2.17 (0.90–5.22) NS Depo-Provera or Norplant 1,177 No Yes 1.28 (0.31–5.32) NS 2.01 (0.32–12.61) NS Barrier methods 1,177 No Yes 1.16 (0.42–3.22) NS 1.15 (0.36–3.68) NS Intrauterine device* 1,182 No Yes 0.12 (0.02–0.99) .049 Cytology 1,186 Normal ASCUS 2.14 (0.62–7.33) NS 0.56 (0.16–2.02) NS LSIL 7.56 (2.14–26.70) .002 3.09 (0.75–12.7) NS HSIL 13.47 (3.08–58.89) .001 3.66 (0.71–18.83) NS AGUS 1.30 (0.18–9.48) NS 1.42 (0.07–29.09) NS Pathology 1,186 Normal CIN 1 2.87 (1.29–6.37) .010 2.53 (1.16–5.53) .020 CIN 2/3 13.46 (3.15–57.60) <.001 7.10 (1.37–36.90) .020 Tobacco use† 1,177 No Yes 1.01 (0.48–2.11) NS 0.88 (0.42–1.84) NS Intercourse within 48 hours of sampling 642 No Yes 1.05 (0.65–1.68) NS 1.07 (0.73–1.55) NS Randomization of person collecting sample: clinician or self 408 Self Clinician 0.59 (0.14–2.45) NS 0.51 (0.12–2.18) NS Randomization of technique used first: swab or tampon 1,186 Swab Tampon 1.28 (0.60–2.74) NS 1.92 (0.89–4.14) NS Number of days from previous sampling 1,186 15 or more days 1–14 days 0.82 (0.66–1.00) .055 0.85 (0.70–1.04) NS Sample taken during specific week of menstrual cycle‡ 1,138 Week 1 Week 2 0.98 (0.63–1.52) NS 1.00 (0.76–1.31) NS Week 3 1.04 (0.63–1.72) NS 1.08 (0.80–1.46) NS Week 4 1.17 (0.72–1.93) NS 1.14 (0.80–1.62) NS Week 5 0.80 (0.47–1.36) NS 0.79 (0.52–1.22) NS Clinician double swab vs 2 consecutive self-swabs vs single self-swab vs tampon 1,184 Clinician-directed ecto- and endo-cervical swabs 2 consecutive self-swabs 1 self-swab 0.81 (0.63–1.03) NS 0.84 (0.73–0.96) .010 0.66 (0.51–0.87) .003 0.84 (0.73–0.96) .010 Tampon 0.61 (0.46–0.81) .001 0.85 (0.74–0.96) .013 High–Risk HPV Any HPV Variable* Reference Levels OR (95% CI) P Value OR (95% CI) P Value OR = odds ratio; CI = confidence interval; NS = not significant. *Adjusted for all other variables in this table. † Where week 1 is 0–7 days, week 2 is 8–14 days, week 3 is 15–21 days, week 4 is 22–35 days, and week 5 is 36 or more days. Week 5 includes those women with very late cycles, and women on Depo-Provera or who are menopausal. Intercourse within 48 hours of sampling No Yes 1.05 (0.65–1.69) NS 1.08 (0.73–1.60) NS Number of days from previous sampling 15 or more days 1–14 days 0.87 (0.70–1.10) NS 0.85 (0.69–1.05) NS Sample taken during specific week of menstrual cycle† Week 1 Week 2 1.01 (0.64–1.59) NS 1.02 (0.77–1.35) NS Week 3 1.08 (0.65,1.81) NS 1.12 (0.82–1.54) NS Week 4 1.22 (0.74–2.01) NS 1.18 (0.81–1.70) NS Week 5 0.81 (0.48–1.38) NS 0.82 (0.54–1.25) NS Technique Clinician-directed ecto- and endocervical swabs 2 consecutive self-swabs 0.87 (0.66–1.13) NS 0.91 (0.85–0.98) .015 1 self-swab 0.71 (0.53–0.95) .023 0.91 (0.85–0.98) .015 Tampon 0.66 (0.48–0.90) .009 0.92 (0.86–0.99) .018
Additional Files
Supplemental Table. Percentage of Samples Positive for Human Papillomavirus (HPV) by Sampling Time.
Files in this Data Supplement:
- Supplemental data: Table - PDF file, 1 page, .85 MB.
Jump to section
Related Articles
Cited By...
- Extended HPV Genotyping to Compare HPV Type Distribution in Self- and Provider-Collected Samples for Cervical Cancer Screening
- Vaginal and Urine Self-sampling Compared to Cervical Sampling for HPV-testing with the Cobas 4800 HPV Test
- Cervical human papillomavirus detection is not affected by menstrual phase
- Variability of Vaginal pH Determination by Patients and Clinicians
- Provocative Questions
- In This Issue: Cervical Cancer Screening